Cardiol Therapeutics Inc. (CRDL) Form 6-K — Sep 10, 2026
Cardiol Therapeutics filed a preliminary short form base shelf prospectus in Canada and a corresponding Form F-10 registration statement with the SEC, which once effective will allow it to offer up to US$150 million of Class A common shares, debt securities, warrants, subscription receipts, or units over a 25-month period. No securities are being offered in connection with this announcement.
Key figures
- Shelf Capacity Usd
- US$150 million
- Securities Eligible
- ["Class A common shares","debt securities","warrants","subscription receipts","units"]
- Prior Financing Referenced
- October 2024 financing completed under the company's prior base shelf prospectus
- Shelf Effective Period Months
- 25
- Us Heart Failure Annual Healthcare Cost
- US$30 billion
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.